Navigation Links
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
Date:11/8/2010

Ms. Burris, who will join the company in this capacity on January 3, 2011, is currently a member of the board of directors of OncoGenex, which she joined following the merger with Sonus Pharmaceuticals. Prior to the merger, Ms. Burris had served on the Sonus board of directors since 2004.

"Having the pleasure of working with Michelle on the board of directors, we are confident that we will benefit from her broad range of experience in strategic planning, financial management and operational oversight as we continue to advance our clinical candidates towards commercialization," said Scott Cormack, president and chief executive officer of OncoGenex.

Ms. Burris most recently served as senior vice president and chief operating officer for Trubion Pharmaceuticals, Inc. until its recent acquisition by Emergent BioSolutions, Inc. She joined Trubion in 2006 as senior vice president and chief financial officer after holding similar positions at Dendreon Corporation and Corixa Corporation. She participated in the development and approval of Bexxar®, an antibody drug approved for the treatment of non-Hodgkin's lymphoma, the negotiation of rights to multiple clinical and pre-clinical product candidates, and the sales of Trubion to Emergent BioSolutions, Inc. and of Corixa to GlaxoSmithKline. Ms. Burris also played an integral role in raising over $600 million of capital through public offerings, other equity transactions and company acquisitions. Prior to entering the biotechnology field, she served in numerous management positions at The Boeing Company and, prior to that, as a research analyst at Cypress International Inc., a Washington, D.C.-based high-technology consulting firm.

"I am joining a management team at OncoGenex with an outstanding track record of delivering on set objectives, advancing clinical programs with speed and efficiency, and creating value from drug development candidates. The company's combination of proven leadership
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Reports Third Quarter Financial Results
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
5. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
6. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. OncoGenex Reports Second Quarter Financial Results
9. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalyst™ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... 2015  S&P Capital IQ (MHFI) announced today ... coverage on Abattis Bioceuticals Corp . ... a specialty biotechnology company with capabilities through its ... proprietary ingredients, bio-similar compounds, patented equipment and consulting ... America . The company seeks to capitalize ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... , , DURHAM, N.C., Sept. ... the company,s proxy, which is being mailed today, asks shareholders to ... Oct. 19, 2009. , , "At last years, ... the counter on the bulletin board and we promised to seek ...
... , , , ... of world leader in hyperbaric medicine ... William I. Preuit to the position of senior vice president of ... leading marketing professional such as Bill to this position shows the ...
... TAI,AN, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- ... ("China Biologic," or the "Company"),one of the ... of China ("PRC"), operating through its indirect ... ("Taibang") and,Chongqing Dalin Biologic Technologies Co., Ltd. ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split 2Sechrist Increases Focus on International Markets; Appoints William Preuit Senior Vice President 2China Biologic Products Appoints Director of Research and Development 2China Biologic Products Appoints Director of Research and Development 3
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... part, responsible for our higher rates of cancer? That,s a ... Tech,s School of Biology and chief research scientist at the ... study, it seems that McDonald is on to something. The ... Hypothesis and will appear in the forthcoming issue of ...
... PROVIDENCE, R.I. [Brown University] BrainGate, an investigational technology ... people with paralysis to use those signals to control ... clinical trial. The system is based on neuroscience, engineering ... BrainGate2 pilot clinical trial is taking place at Massachusetts ...
... Caribbean have been comprehensively ,flattened, over the last 40 years, ... East Anglia (UEA). The collapse of reef structure has ... whammy for fragile coastal communities in the region. ... was in decline, but this is the first large scale ...
Cached Biology News:Brain-computer interface, developed at Brown, begins new clinical trial 2Brain-computer interface, developed at Brown, begins new clinical trial 3Brain-computer interface, developed at Brown, begins new clinical trial 4Caribbean coral reefs flattened 2
... For knockdown of all human, ... siRNAs , Genomewide, predesigned siRNAs ... RNAi , Ready-to-use, convenient matching ... RT-PCR Cost-effective RNAi and ...
... far-infrared range FT-IR spectrometers give you the ... Yet all this comes at an amazingly ... Having a larger and faster mirror closer ... FT-IRs provides 300%,larger solid angle of energy ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... 8800 Genetic Analysis System, which processes two 96-well ... system adds a higher level of throughput to ... part of Beckman Coulters new GenomeLab family of ... the Biomek series liquid handers, for increased automation. ...
Biology Products: